MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ajo.2009.09.026

Медицинская библиотека · American journal of ophthalmology · 2009

Mycophenolate mofetil for ocular inflammation.

Daniel Ebenezer, Thorne Jennifer E, Newcomb Craig W, Pujari Siddharth S, Kaçmaz R Oktay, Levy-Clarke Grace A, Nussenblatt Robert B, Rosenbaum James T, Suhler Eric B, Foster C Stephen, Jabs Douglas A, Kempen John H

СтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАПеревод в очереди

Аннотация

PURPOSE: To evaluate mycophenolate mofetil as a single noncorticosteroid immunosuppressive treatment for noninfectious ocular inflammatory diseases.

DESIGN

Retrospective cohort study.

METHODS

Characteristics of patients with noninfectious ocular inflammation treated with mycophenolate mofetil at 4 subspecialty clinics from 1995 to 2007 were abstracted by expert reviewers in a standardized chart review of every eye at every visit. Main outcomes measured were control of inflammation, corticosteroid-sparing effects, and discontinuation of mycophenolate mofetil (including the reasons for discontinuation). Survival analysis was used to estimate the incidence of outcomes, and to identify risk factors for each.

RESULTS

Among 236 patients (397 eyes) treated with mycophenolate mofetil monotherapy, 20.3%, 11.9%, and 39.8% had anterior uveitis, intermediate uveitis, and posterior uveitis or panuveitis respectively; 14% had scleritis; 7.6% had mucous membrane pemphigoid; and 6.4% had other ocular inflammatory diseases. By Kaplan-Meier estimation, complete control of inflammation--sustained over consecutive visits spanning at least 28 days--was achieved in 53% and 73% of patients within 6 months and 1 year respectively. Systemic corticosteroid dosage was reduced to 10 mg of prednisone or less, while maintaining sustained control of inflammation, in 41% and 55% of patients in 6 months and 1 year respectively. Twelve percent of patients discontinued mycophenolate mofetil within the first year because of side effects of therapy.

CONCLUSIONS

Given sufficient time, mycophenolate mofetil was effective in managing ocular inflammation in approximately half of the treated patients. Treatment-limiting side effects were observed in 12% of patients and typically were reversible.

Для цитирования: Daniel Ebenezer, Thorne Jennifer E, Newcomb Craig W, Pujari Siddharth S, Kaçmaz R Oktay, Levy-Clarke Grace A, Nussenblatt Robert B, Rosenbaum James T, Suhler Eric B, Foster C Stephen, Jabs Douglas A, Kempen John H. Mycophenolate mofetil for ocular inflammation.. American journal of ophthalmology. 2009. DOI: 10.1016/j.ajo.2009.09.026.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.